Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C8H9NO2S |
| Molecular Weight | 183.228 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[S+]([O-])CC(=O)C1=CC=CC=N1
InChI
InChIKey=DSWLRNLRVBAVFC-UHFFFAOYSA-N
InChI=1S/C8H9NO2S/c1-12(11)6-8(10)7-4-2-3-5-9-7/h2-5H,6H2,1H3
Oxisuran was developed by Parke-Davis as an antineoplastic agent. It was shown that this drug was a differential inhibitor of cell-mediated hypersensitivity. Experiments on rodents with experimental autoimmune encephalomyelitis have revealed that oxisuran was pharmacologically effective. However, information about the further development of the compound is not available.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Rodent carcinogenesis bioassay with oxisuran, a selective immunosuppressive agent. | 1983-09 |
|
| Effect of immunosuppressive agents on human T and B lymphoblasts. | 1983-03-01 |
|
| Oxisuran: influence on allograft rejection and graft versus host reactivity in chickens and mice. | 1982-02 |
|
| Oxisuran and immune reactions: mediation of oxisuran action by the adrenal glands. | 1975-12 |
|
| Oxisuran: a differential inhibitor of cell-mediated hypersensitivity. | 1972-03 |
Patents
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C574
Created by
admin on Mon Mar 31 17:54:19 GMT 2025 , Edited by admin on Mon Mar 31 17:54:19 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
NJM3553DH2
Created by
admin on Mon Mar 31 17:54:19 GMT 2025 , Edited by admin on Mon Mar 31 17:54:19 GMT 2025
|
PRIMARY | |||
|
C100291
Created by
admin on Mon Mar 31 17:54:19 GMT 2025 , Edited by admin on Mon Mar 31 17:54:19 GMT 2025
|
PRIMARY | |||
|
CHEMBL2106596
Created by
admin on Mon Mar 31 17:54:19 GMT 2025 , Edited by admin on Mon Mar 31 17:54:19 GMT 2025
|
PRIMARY | |||
|
100000083048
Created by
admin on Mon Mar 31 17:54:19 GMT 2025 , Edited by admin on Mon Mar 31 17:54:19 GMT 2025
|
PRIMARY | |||
|
DTXSID60865359
Created by
admin on Mon Mar 31 17:54:19 GMT 2025 , Edited by admin on Mon Mar 31 17:54:19 GMT 2025
|
PRIMARY | |||
|
C90874
Created by
admin on Mon Mar 31 17:54:19 GMT 2025 , Edited by admin on Mon Mar 31 17:54:19 GMT 2025
|
PRIMARY | |||
|
SUB09539MIG
Created by
admin on Mon Mar 31 17:54:19 GMT 2025 , Edited by admin on Mon Mar 31 17:54:19 GMT 2025
|
PRIMARY | |||
|
2822
Created by
admin on Mon Mar 31 17:54:19 GMT 2025 , Edited by admin on Mon Mar 31 17:54:19 GMT 2025
|
PRIMARY | |||
|
27302-90-5
Created by
admin on Mon Mar 31 17:54:19 GMT 2025 , Edited by admin on Mon Mar 31 17:54:19 GMT 2025
|
PRIMARY | |||
|
356716
Created by
admin on Mon Mar 31 17:54:19 GMT 2025 , Edited by admin on Mon Mar 31 17:54:19 GMT 2025
|
PRIMARY | |||
|
33770
Created by
admin on Mon Mar 31 17:54:19 GMT 2025 , Edited by admin on Mon Mar 31 17:54:19 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
